Andere talen Aerovate Therapeutics, Inc.

Aandelen

AVTE

US0080641071

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,66 ^USD	-0,60%		+6,41%	-92,66%

18/06	Top Middag Decliners	MT
18/06	AEROVATE THERAPEUTICS, INC. : Guggenheim verlaagt advies naar Neutraal	ZM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC	21/06
Top Midday Decliners	18/06
Sector Update: Health Care Stocks Retreat Late Afternoon	17/06
Sector Update: Health Care	17/06
Top Midday Decliners	17/06
Aerovate Therapeutics Plunges after Prospective Hypertension Medication Misses Targets in Phase 2 Study, Scraps More Testing	17/06
Aerovate scraps late-stage study of lung disorder drug	17/06
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails	17/06
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	17/06
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2B Portion of Impahct Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	17/06
Aerovate Therapeutics : June 2024 Corporate Presentation	01/06
Aerovate Therapeutics : May 2024 Corporate Presentation	21/05
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference	21/05
Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	13/05
Aerovate Therapeutics : May 2024 Corporate Presentation	02/05
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	12/04
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	04/04
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	27/03
Aerovate Therapeutics Q4 Loss Widens	25/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aerovate Therapeutics, Inc.

Aandelen

AVTE

US0080641071

Andere talen

Filters